PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.
Enabling measure of 10K+ proteins in FFPE tissue & tumors and multi-omic molecular mapping of tumor biology.
The innovations enhance how MS data is processed, filtered & interpreted across large-scale biological datasets.
Bridging the gap from large-scale omics data generation to deep characterization of disease & treatment biomarkers.
Detailing the rLC-MS method & its use to predict clinically relevant physiological states at scale in human populations.
Exploring key innovations have converged to transform the utility of proteomics in drug discovery & development.
See why DynamiQ is among the most deeply phenotyped datasets available for longitudinal analysis in drug development.
This multi-omics study, led by UPitt researchers, establishes causative linkages between key metabolites & PAH.
See how the partnership complements Sapient’s mass spectrometry-based proteomics & multi-omics services.
Dr. Jonathan Usuka appointed Chief Executive Officer as Founder Dr. Mohit Jain transitions to Chief Scientific Officer.
The Foundation's Impact Report highlights breakthroughs in our collaboration on the first diagnostic for persistent Lyme.
Biocom California spotlights how Sapient is making waves in drug development through dynamic biomarker discovery.
